181 related articles for article (PubMed ID: 7263069)
21. [Muramyl dipeptide and its synthetic analog as possible inducers of interleukin-2 production].
Malaĭtsev VV; Bogdanov IM; Sukhikh GT; Andronova TM
Biull Eksp Biol Med; 1985 Aug; 100(8):221-3. PubMed ID: 3875372
[TBL] [Abstract][Full Text] [Related]
22. Chemical synthesis and adjuvant activity of N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP) analogs 1, 2.
Kamisango K; Saiki I; Tanio Y; Kobayashi S; Fukuda T; Sekikawa I; Azuma I; Yamamura Y
Chem Pharm Bull (Tokyo); 1981 Jun; 29(6):1644-54. PubMed ID: 7296716
[No Abstract] [Full Text] [Related]
23. The muramyl dipeptide analog GMTP-N-DPG preferentially induces cellular immunity to soluble antigens.
Fast DJ; Vosika GJ
Vaccine; 1997 Nov; 15(16):1748-52. PubMed ID: 9364678
[TBL] [Abstract][Full Text] [Related]
24. Enhancement by murabutide of the immune response to natural and synthetic hepatitis B surface antigens.
Audibert FM; Przewlocki G; Leclerc CD; Jolivet ME; Gras-Masse HS; Tartar AL; Chedid LA
Infect Immun; 1984 Jul; 45(1):261-6. PubMed ID: 6735468
[TBL] [Abstract][Full Text] [Related]
25. Enhancement by muramyl dipeptide of in vitro nude mice responses to a T-dependent antigen.
Leclerc C; Bourgeois E; Chedid L
Immunol Commun; 1979; 8(1):55-64. PubMed ID: 311334
[TBL] [Abstract][Full Text] [Related]
26. Immunoadjuvant activities of synthetic N-acetyl-muramyl-peptides or -amino acids.
Kotani S; Watanabe Y; Kinoshita F; Shimono T; Morisaki I
Biken J; 1975 Jun; 18(2):105-11. PubMed ID: 1180867
[TBL] [Abstract][Full Text] [Related]
27. Correlation between in vivo anti-Pseudomonas and anti-Candida activities and clearance of carbon by the reticuloendothelial system for various muramyl dipeptide analogs, using normal and immunosuppressed mice.
Fraser-Smith EB; Waters RV; Matthews TR
Infect Immun; 1982 Jan; 35(1):105-10. PubMed ID: 7054119
[TBL] [Abstract][Full Text] [Related]
28. Opposite effects of the synthetic adjuvant N-acetyl-muramyl-L-alanyl-D-isoglutamine on the immune response in mice depending on experimental conditions.
Souvannavong V; Adam A
Eur J Immunol; 1980 Aug; 10(8):654-6. PubMed ID: 6995138
[TBL] [Abstract][Full Text] [Related]
29. [Inhibition of IgE antibody formation by tubercle bacilli and muramyl peptide].
Kishimoto T
Kekkaku; 1980 Oct; 55(10):467-70. PubMed ID: 6785511
[No Abstract] [Full Text] [Related]
30. Immunoadjuvant effects of the synthetic muramyl-dipeptide (MDP) N-acetylmuramyl-L-alanyl-D-isoglutamine.
Heymer B; Finger H; Wirsing CH
Z Immunitatsforsch Immunobiol; 1978 Oct; 155(1):87-92. PubMed ID: 706536
[TBL] [Abstract][Full Text] [Related]
31. Activation of immune responses by muroctasin.
Akasaki M
Arzneimittelforschung; 1988 Jul; 38(7A):976-7. PubMed ID: 3056427
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant and antitumor activities of quinonyl-N-acetylmuramyldipeptides.
Azuma I; Yamawaki M; Uemiya M; Saiki I; Tanio Y; Kobayashi S; Fukuda T; Imada I; Yamamura Y
Gan; 1979 Dec; 70(6):847-8. PubMed ID: 535688
[No Abstract] [Full Text] [Related]
33. Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity.
Byars NE; Allison AC
Vaccine; 1987 Sep; 5(3):223-8. PubMed ID: 3499713
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant activity of synthetic 6-O-"mycoloyl"-N-acetylmuramyl-L-alanyl-D-isoglutamine and related compounds.
Azuma I; Sugimura K; Yamawaki M; Uemiya M; Kusumoto S; Okada S; Shiba T; Yamamura Y
Infect Immun; 1978 Jun; 20(3):600-7. PubMed ID: 97234
[TBL] [Abstract][Full Text] [Related]
35. Macrophage activation by mycobacterial water soluble compounds and synthetic muramyl dipeptide.
Wahl SM; Wahl LM; McCarthy JB; Chedid L; Mergenhagen SE
J Immunol; 1979 Jun; 122(6):2226-31. PubMed ID: 221582
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant activity of 6-O-mycoloyl derivatives of N-acetylmuramyl-L-seryl-D-isoglutamine and related compounds in mice and guinea pigs.
Uemiya M; Sugimura K; Kusama T; Saiki I; Yamawaki M; Azuma I; Yamamura Y
Infect Immun; 1979 Apr; 24(1):83-9. PubMed ID: 313372
[TBL] [Abstract][Full Text] [Related]
37. Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity.
Chedid LA; Parant MA; Audibert FM; Riveau GJ; Parant FJ; Lederer E; Choay JP; Lefrancier PL
Infect Immun; 1982 Feb; 35(2):417-24. PubMed ID: 7035362
[TBL] [Abstract][Full Text] [Related]
38. Regression of line-10 hepatocarcinoma with synthetic quinonyl muramyl dipeptide in strain-2 guinea pigs.
Tanio Y; Souma H; Tokushima Y; Yamamura Y; Azuma I
Gan; 1983 Apr; 74(2):192-5. PubMed ID: 6862142
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant formulations and their mode of action.
Allison AC; Byars NE
Semin Immunol; 1990 Sep; 2(5):369-74. PubMed ID: 1966859
[TBL] [Abstract][Full Text] [Related]
40. Induction of murine macrophage tumoricidal activity and treatment of experimental pulmonary metastases by liposomes containing lipophilic muramyl dipeptide analogs.
Phillips NC; Chedid L; Bernard JM; Level M; Lefrancier P
J Biol Response Mod; 1987 Dec; 6(6):678-91. PubMed ID: 3450784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
